Actualités et communiqués de presse Instil Bio 2026 | TIL | ISIN US45783C2008

Actualités Eulerpool Instil Bio

Actualités de l'action Instil Bio

Instil Bio est suivi par de nombreux journalistes et investisseurs dans le monde. Nous rassemblons ici les dernières actualités concernant Instil Bio.

7 janvier·
Benzinga
HC Wainwright & Co. Downgrades Instil Bio to Neutral
13 novembre·
Benzinga
Instil Bio Q3 Adj. EPS $(1.75) Beats $(2.35) Estimate
2 juillet·
Yahoo
Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors
2 juillet·
Benzinga
Instil Bio shares are trading higher after the company announced it received FDA Clearance for IND of AXN-2510.
2 juillet·
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
2 juillet·
Benzinga
Instil Bio Gets US FDA Clearance For IND Of AXN-2510, A PD-L1xVEGF Bispecific Antibody, With Phase 1 Solid Tumor Trial Set For 2025
20 juin·
Yahoo
Instil Bio, Inc. (TIL) Is Up 4.07% in One Week: What You Should Know
16 juin·
Yahoo
Wall Street Analysts Think Instil Bio (TIL) Could Surge 246.68%: Read This Before Placing a Bet
11 juin·
Yahoo
Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program
4 juin·
Yahoo
Are You Looking for a Top Momentum Pick? Why Instil Bio, Inc. (TIL) is a Great Choice
2 juin·
Yahoo
Instil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer
30 mai·
Yahoo
Instil Bio to Participate in the 2025 Jefferies Global Healthcare Conference
29 mai·
Yahoo
Wall Street Analysts Believe Instil Bio (TIL) Could Rally 343.63%: Here's is How to Trade
26 mai·
SeekingAlpha
Investing In The Promising PD1/VEGF Bispecific - Pfizer And Instil Could Be Good Candidates
25 mai·
SeekingAlpha
Instil Bio: Second-Half 2025 AXN-2510 Data Could Mark Another PD-1/VEGF Success
13 mai·
Benzinga
Instil Bio Q1 Adj. EPS $(1.32) Beats $(2.59) Estimate
4 mars·
Yahoo
Instil Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
2 mars·
Yahoo
Jefferies Predicts Up to ~500% Jump for These 2 ‘Strong Buy’ Stocks
20 février·
Yahoo
Private equity firms who hold 38% of Instil Bio, Inc. (NASDAQ:TIL) gained 34%, institutions profited as well
12 février·
SeekingAlpha
Invesco Main Street Small Cap Fund Q4 2024 Commentary

Communiqués de presse relatifs à l'action Instil Bio

Instil Bio publie régulièrement sur son site web des communiqués pertinents pour les investisseurs.

12 août•
Instil Bio
Instil Bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update
27 mai•
Instil Bio
Instil Bio Announces IND Clearance of First CoStAR-TIL program, ITIL-306, Designed to Enhance Activity in the Tumor Microenvironment
18 mai•
Instil Bio
Instil Bio to Present Novel TIL Analytics at American Society of Gene and Cell Therapy (ASGCT)
16 mai•
Instil Bio
Instil Bio Reports First Quarter 2022 Financial Results and Provides Corporate Update
7 mars•
Instil Bio
Instil Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
2 mars•
Instil Bio
Instil Bio to Present at the Cowen 42nd Annual Health Care Conference
15 novembre•
Instil Bio
Instil Bio Reports Third Quarter 2021 Financial Results and Provides Corporate Update
8 novembre•
Instil Bio
Instil Bio to Present at Upcoming Investor Conferences in November
16 septembre•
Instil Bio
Instil Bio Presents Subset Analysis of Patients with Checkpoint-Refractory Advanced Melanoma from Compassionate Use Study at 2021 ESMO Congress
13 septembre•
Instil Bio
Instil Bio Receives IND Clearance to Initiate a Phase 2 Clinical Trial for Patients with Advanced Melanoma
2 septembre•
Instil Bio
Instil Bio to Present at Upcoming Investor Conferences in September
12 août•
Instil Bio
Instil Bio Reports Second Quarter 2021 Financial Results and Provides Corporate Update
1 juin•
Instil Bio
Instil Bio to Present at the Jefferies Virtual Healthcare Conference
13 mai•
Instil Bio
Instil Bio Reports First Quarter 2021 Financial Results and Provides Corporate Update
27 avril•
Instil Bio
Instil Bio Receives Orphan Drug Designation for ITIL-168 in Melanoma
12 avril•
Instil Bio
Instil Bio Presents Clinical Data in Metastatic Melanoma in a Late-Breaking e-Poster at the 2021 American Association for Cancer Research (AACR) Annual Meeting
23 mars•
Instil Bio
Instil Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
18 mars•
Instil Bio
Instil Bio Announces Pricing of Upsized Initial Public Offering

Instil Bio News 2026

Cette page contient toutes les actualités actuelles, analyses et communiqués de presse pour l'action Instil Bio (TIL, ISIN : US45783C2008). Cela inclut les actualités Eulerpool, les analyses d'entreprise et les communiqués de presse officiels. Les données sont mises à jour régulièrement pour fournir aux investisseurs un aperçu complet des derniers développements chez Instil Bio.